Vaccination of African penguins (Spheniscus demersus) against high-pathogenicity avian influenza

Show simple item record

dc.contributor.author Roberts, Laura Christl
dc.contributor.author Abernethy, D.A. (Darrell)
dc.contributor.author Roberts, David Gordon
dc.contributor.author Ludynia, Katrin
dc.contributor.author O'Kennedy, Martha Magaretha
dc.contributor.author Abolnik, Celia
dc.date.accessioned 2024-01-09T07:45:19Z
dc.date.available 2024-01-09T07:45:19Z
dc.date.issued 2024-01
dc.description DATA AVAILABILITY STATEMENT : The data that support the findings of this study are available from the corresponding author upon reasonable request. en_US
dc.description.abstract BACKGROUND : High-pathogenicity avian influenza (HPAI) has become a conservation threat to wild birds. Therefore, suitable vaccine technology and practical application methods require investigation. METHODS : Twenty-four African penguins (Spheniscus demersus) were vaccinated with either a conventional inactivated clade 2.3.4.4b H5N8 HPAI whole virus or a tobacco leaf-produced H5 haemagglutinin-based virus-like particle (VLP). Six birds received a second dose of the inactivated vaccine. Antibody responses were assessed and compared by employing haemagglutination inhibition tests. RESULTS : A second dose of inactivated vaccine was required to induce antibody titres above the level required to suppress virus shedding, while a single dose of VLP vaccine produced these levels by day 14, and one bird still had antibodies on day 430. LIMITATIONS : Bacterial contamination of the VLP vaccine limited the monitoring period and sample size in that treatment group, and it was not possible to perform a challenge study with field virus. CONCLUSION : VLP vaccines offer a more practical option than inactivated whole viruses, especially in logistically challenging situations involving wild birds. en_US
dc.description.department Centre for Veterinary Wildlife Studies en_US
dc.description.department Production Animal Studies en_US
dc.description.librarian hj2023 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship NRF-DSI SARChI and Health and Welfare Sector Education and Training Authority. en_US
dc.description.uri https://wileyonlinelibrary.com/journal/vetr en_US
dc.identifier.citation Roberts, L.C., Abernethy, D., Roberts, D.G., Ludynia, K., O'Kennedy, M.M. & Abolnik, C. Vaccination of African penguins (Spheniscus demersus) against high-pathogenicity avian influenza. Veterinary Record 2024, vol. 194, no. 2, art. e3616, pp. 1-5, https://doi.org/10.1002/vetr.3616. en_US
dc.identifier.issn 0042-4900 (print)
dc.identifier.issn 2042-7670 (online)
dc.identifier.other 10.1002/vetr.3616
dc.identifier.uri http://hdl.handle.net/2263/93867
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.rights © 2023 The Authors. Veterinary Record published by John Wiley & Sons Ltd on behalf of British Veterinary Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License. en_US
dc.subject High-pathogenicity avian influenza (HPAI) en_US
dc.subject African penguins (Spheniscus demersus) en_US
dc.subject Wild birds en_US
dc.subject Virus-like particle (VLP) en_US
dc.subject VLP vaccine en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Vaccination of African penguins (Spheniscus demersus) against high-pathogenicity avian influenza en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record